Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Immunovant, Inc. (IMVT : NSDQ)
 
 • Company Description   
Immunovant Inc. is a clinical-stage biopharmaceutical company focused on autoimmune diseases. The company's product candidate consists of IMVT-1401 which is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor which is in clinical stage. Immunovant Inc. is based in New York, United States.

Number of Employees: 68

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.02 Daily Weekly Monthly
20 Day Moving Average: 379,467 shares
Shares Outstanding: 116.40 (millions)
Market Capitalization: $467.91 (millions)
Beta: 0.96
52 Week High: $16.05
52 Week Low: $3.71
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -19.44% -11.73%
12 Week -26.78% -20.55%
Year To Date -52.82% -43.89%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
320 WEST 37TH STREET
-
NEW YORK,NY 10018
USA
ph: 917-580-3099
fax: -
info@immunovant.com http://www.immunovant.com
 
 • General Corporate Information   
Officers
Peter Salzmann - Chief Executive Officer and Director
Frank M. Torti - Chairman
Pamela Yanchik Connealy - Chief Financial Officer
Andrew Fromkin - Director
Douglas Hughes - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45258J102
SIC: 2836
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 06/07/22
Share - Related Items
Shares Outstanding: 116.40
Most Recent Split Date: (:1)
Beta: 0.96
Market Capitalization: $467.91 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.67 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/07/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.92
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -12.50%
vs. Previous Quarter: -2.86%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -30.63
09/30/21 - -30.01
ROA
03/31/22 - -
12/31/21 - -28.83
09/30/21 - -28.46
Current Ratio
03/31/22 - -
12/31/21 - 14.87
09/30/21 - 19.86
Quick Ratio
03/31/22 - -
12/31/21 - 14.87
09/30/21 - 19.86
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 4.39
09/30/21 - 4.66
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©